Report cover image

Chiesi Farmaceutici S.p.A. (:BIT) - Strategic SWOT Spotlight

Publisher Quaintel Research
Published Aug 27, 2024
Length 52 Pages
SKU # QTELR19119621

Description

Chiesi Farmaceutici S.p.A. (:BIT) - Strategic SWOT Spotlight


Chiesi Farmaceutici S.p.A. (:BIT) - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The Chiesi Farmaceutici S.p.A.'s business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.

Key Highlights

Chiesi Farmaceutici S.p.A. is a pharmaceutical company that operates globally, with a focus on research, development, and production of innovative medicines. They offer a wide range of products and services in various therapeutic areas, including respiratory, neonatology, rare diseases, and special care. Their respiratory portfolio includes treatments for asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. In the neonatology field, they provide treatments for respiratory distress syndrome and other neonatal conditions. Chiesi also offers treatments for rare diseases such as alpha-1 antitrypsin deficiency and lysosomal storage disorders. Additionally, they have a special care division that provides products for patients with chronic conditions such as diabetes and cardiovascular diseases. Overall, Chiesi Farmaceutici S.p.A. is committed to improving the health and well-being of patients through their innovative and high-quality pharmaceutical products and services. Founded in 1935, the company is headquartered in Parma, Emilia-Romagna, Italy.

Chiesi Farmaceutici S.p.A. in the News:-
  • 18-Mar-2024 - Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
  • 04-Mar-2024 - Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
  • 08-Jan-2024 - Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
  • 18-Dec-2023 - Chiesi was awarded the 59 Oscar di Bilancio for the Benefit Corporation category
  • 27-Oct-2023 - Chiesi Foundation's NEST Partners Meeting in Sub-Saharan Africa
Scope

Company Fundamentals:- These fundamentals offer valuable insights into Chiesi Farmaceutici S.p.A. (:BIT)'s operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.

Reasons to Buy
  • Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Table of Contents

52 Pages
Table of Contents
Tables
Charts
Chiesi Farmaceutici S.p.A. - Key Company Facts
Chiesi Farmaceutici S.p.A. - Company Description
Chiesi Farmaceutici S.p.A. - Top Executives
Chiesi Farmaceutici S.p.A. - Head Office & Locations
Head Office - Country
Chiesi Farmaceutici S.p.A. - Products and Services
Products
Services
Chiesi Farmaceutici S.p.A. - Corporate Strategy
Chiesi Farmaceutici S.p.A. - Business Description
Respiratory Products
Rare Diseases
Specialty Medicines
Chiesi Farmaceutici S.p.A. - ESG Spotlight
Environment
Social
Corporate Governance
Chiesi Farmaceutici S.p.A. - SWOT Spotlight
Overview
Strengths
Weaknesses
Opportunities
Threats
Competing Players
Snapshot of Competing Players
Newron Pharmaceuticals SpA
Key Company Facts
Company Description
Key Financials:
Recordati Industria Chimica e Farmaceutica S.p.A
Key Company Facts
Company Description
Key Financials:
Teva Pharmaceutical Industries Limited
Key Company Facts
Company Description
Key Financials:
Alfasigma S.p.A
Key Company Facts
Company Description
Cosmo Pharmaceuticals NV
Key Company Facts
Company Description
Key Financials:
Chiesi Farmaceutici S.p.A. - In the News
18-Mar-2024- Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
04-Mar-2024- Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation 08-Jan-2024- Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
18-Dec-2023- Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
27-Oct-2023- Chiesi Foundation's NEST Partners Meeting in Sub-Saharan Africa
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us